Lipid-anchored drugs for delivery into subcellular compartments

Trends in Pharmacological Sciences

Volumn 33, Issue 4, 2012, Pages 215-222

  Rajendran, Lawrence ^a   Udayar, Vinod ^a   Goodger, Zoë V ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BETA SECRETASE; CYTARABINE; ELACYTARABINE; G PROTEIN COUPLED RECEPTOR; IMETELSTAT; LIPID; LIPOSOME; NOOTROPIC AGENT; OLIGONUCLEOTIDE; POKEWEED ANTIVIRUS PROTEIN; SMALL INTERFERING RNA;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CELL COMPARTMENTALIZATION; CELL SELECTION; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG TARGETING; ENDOCYTOSIS; ENDOSOME; EXOSOME; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID RAFT; LIPOPHILICITY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN TRANSPORT; REVIEW; RNA INTERFERENCE; TRANSCYTOSIS;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; INTRACELLULAR SPACE; LIPIDS; MEMBRANE TRANSPORT PROTEINS; PHARMACEUTICAL PREPARATIONS; RECEPTORS, CELL SURFACE;

EID: 84859440263     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2012.01.006     Document Type: Review

References (60)

1. G. Levy, and L.E. Hollister Dissolution rate limited absorption in man. Factors influencing drug absorption from prolonged-release dosage form J. Pharm. Sci. 54 1965 1121 1125
2. H. Rosen, and T. Abribat The rise and rise of drug delivery Nat. Rev. Drug Discov. 4 2005 381 385
3. C.W. Pouton Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems Eur. J. Pharm. Sci. 11 Suppl. 2 2000 S93 S98
4. F.R. Maxfield, and T.E. McGraw Endocytic recycling Nat. Rev. Mol. Cell Biol. 5 2004 121 132
5. L. Rajendran, and K. Simons Lipid rafts and membrane dynamics J. Cell Sci. 118 2005 1099 1102
6. W. Stoorvogel The biogenesis and functions of exosomes Traffic 3 2002 321 330
7. L. Alvarez-Erviti Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes Nat. Biotechnol. 29 2011 341 345
8. M. Koivusalo Endocytic trafficking of sphingomyelin depends on its acyl chain length Mol. Biol. Cell 18 2007 5113 5123
9. G. van Meer Membrane lipids: where they are and how they behave Nat. Rev. Mol. Cell Biol. 9 2008 112 124
10. S. Mukherjee, and F.R. Maxfield Role of membrane organization and membrane domains in endocytic lipid trafficking Traffic 1 2000 203 211
11. V. Puri Clathrin-dependent and -independent internalization of plasma membrane sphingolipids initiates two Golgi targeting pathways J. Cell Biol. 154 2001 535 547
12. L. Johannes, and D. Decaudin Protein toxins: intracellular trafficking for targeted therapy Gene Ther. 12 2005 1360 1368
13. L. Rajendran Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting Science 320 2008 520 523
14. S. Gilch, and H.M. Schatzl Aptamers against prion proteins and prions Cell. Mol. Life Sci. 66 2009 2445 2455
15. Q. Sun Selective disruption of early/recycling endosomes: release of disulfide-linked cargo mediated by a N-alkyl-3beta-cholesterylamine-capped peptide J. Am. Chem. Soc. 130 2008 10064 10065
16. S. Boonyarattanakalin Synthetic mimics of small mammalian cell surface receptors J. Am. Chem. Soc. 126 2004 16379 16386
17. S. Ben Halima, and L. Rajendran Membrane anchored and lipid raft targeted beta-secretase inhibitors for Alzheimer's disease therapy J. Alzheimers Dis. 24 Suppl. 2 2011 143 152
18. L. Rajendran Alzheimer's disease beta-amyloid peptides are released in association with exosomes Proc. Natl. Acad. Sci. U.S.A. 103 2006 11172 11177
19. B. Schmidt Inhibitors and modulators of beta- and gamma-secretase Curr. Top. Med. Chem. 6 2006 377 392
20. B. Schmidt Modulators and inhibitors of gamma- and beta-secretases Neurodegener. Dis. 3 2006 290 297
21. G. Adam, and M. Delbruck Reduction of Dimensionality in Biological Diffusion Processes 1968 W.H. Freeman
22. P. Ingallinella Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency Proc. Natl. Acad. Sci. U.S.A. 106 2009 5801 5806
23. P. Gripon Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein J. Virol. 79 2005 1613 1622
24. J. Petersen Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein Nat. Biotechnol. 26 2008 335 341
25. C.M. Galmarini Cytotoxic nucleoside analogues: different strategies to improve their clinical efficacy Curr. Med. Chem. 15 2008 1072 1082
26. F. Li Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting J. Pharm. Sci. 97 2008 1109 1134
27. A.M. Bergman Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines Biochem. Pharmacol. 67 2004 503 511
28. D.M. Lambert Rationale and applications of lipids as prodrug carriers Eur. J. Pharm. Sci. 11 Suppl. 2 2000 S15 S27
29. W. Rubas Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes Int. J. Cancer 37 1986 149 154
30. S. Dueland Intravenous administration of CP-4055 (ELACYT) in patients with solid tumours. A Phase I study Acta Oncol. 48 2009 137 145
31. L. Covic Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation Nat. Med. 8 2002 1161 1165
32. L. Covic Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides Proc. Natl. Acad. Sci. U.S.A. 99 2002 643 648
33. R.B. Campbell Phospholipid-cationic lipid interactions: influences on membrane and vesicle properties Biochim. Biophys. Acta 1512 2001 27 39
34. S. Sinha A lipid-modified estrogen derivative that treats breast cancer independent of estrogen receptor expression through simultaneous induction of autophagy and apoptosis Mol. Cancer Res. 9 2011 364 374
35. L. Rajendran Subcellular targeting strategies for drug design and delivery Nat. Rev. Drug Discov. 9 2010 29 42
36. V.P. Torchilin Recent approaches to intracellular delivery of drugs and DNA and organelle targeting Annu. Rev. Biomed. Eng. 8 2006 343 375
37. N.W. Kim Specific association of human telomerase activity with immortal cells and cancer Science 266 1994 2011 2015
38. B.S. Herbert Lipid modification of GRN163, an N3′→P5′ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition Oncogene 24 2005 5262 5268
39. T.P. Herringson, and J.G. Altin Convenient targeting of stealth siRNA-lipoplexes to cells with chelator lipid-anchored molecules J. Control Release 139 2009 229 238
40. D.V. Morrissey Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs Nat. Biotechnol. 23 2005 1002 1007
41. D.B. Rozema Dynamic polyconjugates for targeted in vivo delivery of siRNA to hepatocytes Proc. Natl. Acad. Sci. U.S.A. 104 2007 12982 12987
42. A. Akinc A combinatorial library of lipid-like materials for delivery of RNAi therapeutics Nat. Biotechnol. 26 2008 561 569
43. C. Wolfrum Mechanisms and optimization of in vivo delivery of lipophilic siRNAs Nat. Biotechnol. 25 2007 1149 1157
44. K.C. Vickers MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins Nat. Cell Biol. 13 2011 423 433
45. H. Valadi Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells Nat. Cell Biol. 9 2007 654 659
46. M.L. Immordino Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential Int. J. Nanomed. 1 2006 297 315
47. Y.S. Park Tumor-directed targeting of liposomes Biosci. Rep. 22 2002 267 281
48. S. Sofou, and G. Sgouros Antibody-targeted liposomes in cancer therapy and imaging Expert Opin. Drug Deliv. 5 2008 189 204
49. M.D. Pegram Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment J. Clin. Oncol. 16 1998 2659 2671
50. G. Winter, and W.J. Harris Humanized antibodies Trends Pharmacol. Sci. 14 1993 139 143
51. Y. Zhang Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism Hum. Gene Ther. 14 2003 1 12
52. Y. Zhang, and W.M. Pardridge Near complete rescue of experimental Parkinson's disease with intravenous, non-viral GDNF gene therapy Pharm. Res. 26 2009 1059 1063
53. Y.J. Yu Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target Sci. Transl. Med. 3 2011 84ra44
54. V. Soubannier A vesicular transport pathway shuttles cargo from mitochondria to lysosomes Curr. Biol. 22 2012 135 141
55. J. Rautio Prodrugs: design and clinical applications Nat. Rev. Drug Discov. 7 2008 255 270
56. Q.T. Nguyen Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival Proc. Natl. Acad. Sci. U.S.A. 107 2010 4317 4322
57. C.A. Lipinski Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 46 2001 3 26
58. K. Cho Therapeutic nanoparticles for drug delivery in cancer Clin. Cancer Res. 14 2008 1310 1316
59. V. Dixit Synthesis and grafting of thioctic acid-PEG-folate conjugates onto Au nanoparticles for selective targeting of folate receptor-positive tumor cells Bioconjug. Chem. 17 2006 603 609
60. S.K. Sahoo, and V. Labhasetwar Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention Mol. Pharm. 2 2005 373 383